Last reviewed · How we verify
PSEUDOEPHEDRINE SULFATE
Pseudoephedrine sulfate is a marketed drug primarily indicated for the relief of hay fever symptoms. Its key strength lies in its well-established market presence and the key composition patent, which is set to expire in 2028. The primary risk is the potential increase in competition following the patent expiry.
At a glance
| Generic name | PSEUDOEPHEDRINE SULFATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1963 |
Approved indications
- Relief of hay fever symptoms
- Relief of nasal congestion
- Reduction of nasal passage swelling
- Relief of sinus congestion and pressure
- Restoration of nasal breathing
Common side effects
Key clinical trials
- The Noninvasive Blood Pressure Measurement Effect on the Hypotension (NA)
- Intravenous Administration of Magnesium Sulfate in Laparoscopic Hysterectomy Cases (NA)
- Anesthesia Techniques, Neuroprotection and Surgical Field in FESS Under Controlled Hypotension (NA)
- Minimal Flow Anesthesia and Infection Risk (NA)
- Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
- Intravenous Administration of Magnesium Sulfate in Hysterectomy Cases (NA)
- Hemodynamics During Induction of General Anesthesia After Prophylactic Ephedrine, Phenylephrine or Norepinephrine. (PHASE4)
- Dexmedetomidine Infusion Dose Versus Rapid Bolus Dose Before Tracheal Intubation. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |